Study of breast cancer survivors shows that depression and stress, rather than cardiac function decline, are the primary ...

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly ...

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple ...

Oncology nurses share high-level strategies for advanced RCC therapy, focusing on managing hypertension, diarrhea, and ...

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in patients with polycythemia vera. FDA approves BESREMi (ropeginterferon ...

C, of Banner MD Anderson Cancer Center at Banner Gateway Medical Center, reviews the venous thromboembolism (VTE) data behind ...

Having recently moderated a case-based roundtable discussion on triple-negative breast cancer, Iorio shares her clinical ...

A new study shows physical activity increases tumor-killing T cells and reduces suppressive Tregs in obese lung environments, ...

FDA approves daraxonrasib, a first-in-class daily oral RAS inhibitor, doubling survival in metastatic pancreatic ...